Viskase Holdings, Inc.

Enzon Pharmaceuticals, Inc. operates as a public company acquisition vehicle. The company historically generated royalty and milestone revenues through licensing agreements with pharmaceutical partners, primarily based on sales of drug products utilizing its proprietary technology such as PegIntron and Vicineum. However, Enzon maintains no clinical operations and only limited corporate operations. It does not directly manufacture products or maintain commercial business segments, having transitioned its focus toward executing corporate combinations such as its pending merger with Viskase Companies, Inc.

The company operates without direct employees, relying on an executive officer who provides services on a consulting basis. It holds a portfolio of issued Canadian patents with various non-U.S. counterparts, though it maintains no manufacturing facilities or retail operations. Enzon's principal executive offices are situated in Cranford, New Jersey, where it leases administrative space through a shared services agreement.

Summary of the business section of Viskase's latest annual report, written by StockData.

“As of December 31, 2015, we had one employee.”